LT1610784T - 5-azacitidino formos - Google Patents

5-azacitidino formos

Info

Publication number
LT1610784T
LT1610784T LTEP04721074.5T LT04721074T LT1610784T LT 1610784 T LT1610784 T LT 1610784T LT 04721074 T LT04721074 T LT 04721074T LT 1610784 T LT1610784 T LT 1610784T
Authority
LT
Lithuania
Prior art keywords
azacytidine
forms
Prior art date
Application number
LTEP04721074.5T
Other languages
English (en)
Inventor
Dumitru Ionescu
Peter Blumbergs
Lee Alani Selvey
Original Assignee
Celgene International Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32987557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT1610784(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene International Sarl filed Critical Celgene International Sarl
Publication of LT1610784T publication Critical patent/LT1610784T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEP04721074.5T 2003-03-17 2004-03-16 5-azacitidino formos LT1610784T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/390,578 US6887855B2 (en) 2003-03-17 2003-03-17 Forms of 5-azacytidine
PCT/US2004/007895 WO2004082619A2 (en) 2003-03-17 2004-03-16 Forms of 5-azacytidine

Publications (1)

Publication Number Publication Date
LT1610784T true LT1610784T (lt) 2016-10-25

Family

ID=32987557

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP04721074.5T LT1610784T (lt) 2003-03-17 2004-03-16 5-azacitidino formos

Country Status (11)

Country Link
US (7) US6887855B2 (lt)
EP (5) EP1610784B1 (lt)
CY (2) CY1117990T1 (lt)
DK (2) DK2258711T3 (lt)
ES (2) ES2621531T3 (lt)
HU (2) HUE030717T2 (lt)
LT (1) LT1610784T (lt)
PL (2) PL1610784T3 (lt)
PT (2) PT2258711T (lt)
SI (2) SI1610784T1 (lt)
WO (1) WO2004082619A2 (lt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US7759481B2 (en) * 2007-01-11 2010-07-20 Ivax Corporation Solid state forms of 5-azacytidine and processes for preparation thereof
EP2176279A4 (en) * 2007-08-02 2012-01-11 Chemagis Ltd HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
EP2197274A4 (en) * 2007-09-26 2013-03-06 Sinai School Medicine AZACYTIDINE ANALOGS AND USES THEREOF
WO2009058394A1 (en) * 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
ES2969144T3 (es) * 2008-05-15 2024-05-16 Celgene Corp Formulaciones orales de análogos de citidina y métodos de uso de los mismos
WO2010014883A2 (en) 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
WO2010017547A1 (en) * 2008-08-08 2010-02-11 Scinopharm Taiwan Ldt. Process for making 5-azacytosine nucleosides and their derivatives
EP2410987B1 (en) * 2009-03-23 2018-05-16 Ambit Biosciences Corporation Methods of treatment using combination therapy
EP2424845A4 (en) * 2009-04-27 2014-03-05 Reddys Lab Ltd Dr PREPARATION OF DECITABIN
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
ATE534721T1 (de) * 2009-09-14 2011-12-15 Procter & Gamble Reinigungsmittelzusammensetzung
US9249466B2 (en) 2010-01-08 2016-02-02 Agency For Science, Technology And Research Methods and compositions for treating cancer
EP2670396A1 (en) * 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
JP6289361B2 (ja) 2011-03-31 2018-03-07 セルジーン インターナショナル サルル ５−アザシチジンの合成
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
US20130085115A1 (en) 2011-09-23 2013-04-04 Celgene Corporation Combination therapy for lymphoma
JP2014526564A (ja) 2011-09-26 2014-10-06 セルジーン コーポレイション 化学療法抵抗性癌の併用療法
ES2668272T3 (es) 2011-11-03 2018-05-17 Millennium Pharmaceuticals, Inc. Administración de inhibidor de enzimas que activa NEDD8 y agente de hipometilación
WO2014076616A2 (en) * 2012-11-19 2014-05-22 Shilpa Medicare Limited Formulations of 5-azacytidine
US9765108B2 (en) 2012-11-19 2017-09-19 Shilpa Medicare Limited Formulation of 5-azacytidine
US9968627B2 (en) 2013-03-26 2018-05-15 Celgene Corporation Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof
CN103450303A (zh) * 2013-09-04 2013-12-18 重庆泰濠制药有限公司 阿扎胞苷晶型a、阿扎胞苷晶型b及其制备方法
HUE061382T2 (hu) 2014-08-22 2023-06-28 Celgene Corp Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
US20160095925A1 (en) * 2014-10-01 2016-04-07 Cadila Healthcare Limited Stable formulation of azacitidine or salts thereof and their process for preparation
GB2542881B (en) * 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
KR20180067658A (ko) 2015-10-15 2018-06-20 아지오스 파마슈티컬스 아이엔씨. 악성 종양의 치료를 위한 조합물 요법
SG11201802964QA (en) 2015-10-15 2018-05-30 Celgene Corp Combination therapy for treating malignancies
JP2020535112A (ja) 2017-08-01 2020-12-03 ドイッチェス・クレープスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｍｉｄｈ１阻害剤とｄｎａ低メチル化剤（ｈｍａ）との組合せ
CN107827944B (zh) * 2017-11-02 2020-11-24 北京满格医药科技有限公司 一种阿扎胞苷单晶的制备方法
CN109988207B (zh) * 2017-12-29 2022-01-04 江苏豪森药业集团有限公司 阿扎胞苷晶型的制备方法
CA3103436A1 (en) 2018-06-11 2019-12-19 The Regents Of The University Of California Demethylation to treat eye disease
CN110642901A (zh) * 2019-11-11 2020-01-03 扬子江药业集团有限公司 阿扎胞苷甲醇化物及其制备方法和药物组合物、用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (lt) 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5872104A (en) * 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
IL129126A0 (en) 1996-10-16 2000-02-17 Icn Pharmaceuticals Monocyclic l-nucleosides analogs and uses thereof
EP1182204B1 (en) 1999-06-03 2004-04-07 Eisai Co., Ltd. Crystals of carbapenem derivatives and pharmaceutical preparations for injection
ATE312823T1 (de) 1999-07-09 2005-12-15 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
IL154718A0 (en) 2000-09-07 2003-10-31 Kaneka Corp Methods for crystallization of hydroxycarboxylic acids
AU2002335489B2 (en) * 2001-03-01 2008-06-05 Abbott Laboratories Polymorphic and other crystalline forms of cis-FTC
EP1545558A4 (en) * 2002-09-24 2010-02-17 Koronis Pharmaceuticals Inc 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20040162263A1 (en) 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
WO2004069796A2 (en) 2003-02-03 2004-08-19 Teva Pharmaceutical Industries Ltd. Process for producing levetiracetam
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
CN101856348A (zh) 2003-08-29 2010-10-13 斯隆-凯特林癌症研究所 联合治疗癌症的方法
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
US7759481B2 (en) 2007-01-11 2010-07-20 Ivax Corporation Solid state forms of 5-azacytidine and processes for preparation thereof
EP2114152A1 (en) 2007-01-25 2009-11-11 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
EP2176279A4 (en) 2007-08-02 2012-01-11 Chemagis Ltd HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
EP2048151A1 (en) 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
WO2009058394A1 (en) 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
ES2969144T3 (es) 2008-05-15 2024-05-16 Celgene Corp Formulaciones orales de análogos de citidina y métodos de uso de los mismos
WO2010014883A2 (en) 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2520581A1 (en) 2008-08-06 2012-11-07 Sicor, Inc. Method for the determination the purity of 5-Azacytidine
WO2010017547A1 (en) 2008-08-08 2010-02-11 Scinopharm Taiwan Ldt. Process for making 5-azacytosine nucleosides and their derivatives
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina

Also Published As

Publication number Publication date
EP1610784A4 (en) 2007-11-07
US20040186065A1 (en) 2004-09-23
US8779117B2 (en) 2014-07-15
EP2270023A1 (en) 2011-01-05
HUE033508T2 (en) 2017-12-28
US20060247189A1 (en) 2006-11-02
EP2270022B1 (en) 2016-06-29
US6887855B2 (en) 2005-05-03
EP2258711B1 (en) 2017-01-18
EP2258710B1 (en) 2016-10-19
US20130059810A1 (en) 2013-03-07
PL1610784T3 (pl) 2017-02-28
EP2258711B9 (en) 2017-12-27
EP1610784A2 (en) 2006-01-04
ES2621531T3 (es) 2017-07-04
EP2270023B1 (en) 2016-06-15
EP1610784B1 (en) 2016-07-06
US8513406B2 (en) 2013-08-20
PT1610784T (pt) 2016-09-23
DK2258711T3 (en) 2017-04-24
US7078518B2 (en) 2006-07-18
SI2258711T1 (sl) 2017-08-31
US20130059809A1 (en) 2013-03-07
DK1610784T3 (en) 2016-09-12
US7772199B2 (en) 2010-08-10
SI1610784T1 (sl) 2017-01-31
EP2258710A1 (en) 2010-12-08
ES2592287T3 (es) 2016-11-29
HUE030717T2 (en) 2017-05-29
US20140107058A1 (en) 2014-04-17
US9192620B2 (en) 2015-11-24
WO2004082619A2 (en) 2004-09-30
EP2258711A3 (en) 2011-03-30
CY1117990T1 (el) 2017-05-17
WO2004082619A3 (en) 2005-05-26
EP2270022A1 (en) 2011-01-05
CY1118805T1 (el) 2018-01-10
PT2258711T (pt) 2017-03-30
US20100298253A1 (en) 2010-11-25
EP2258711A2 (en) 2010-12-08
PL2258711T3 (pl) 2017-08-31
US8614313B2 (en) 2013-12-24
US20050137150A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
EP1610784A4 (en) FORMS OF 5-AZACYTIDINE
ZA200605348B (en) Solid forms of anti-EGFR-antibodies
GB0325192D0 (en) Method of use
HK1093483A1 (en) Polymorphic form of n-
EP1788874A4 (en) 5-AZACYTIDINE SALTS
AU2003236991A8 (en) Representations of processes
AU2003298725A8 (en) Preparation of metallotexaphyrins
PL377902A1 (pl) Nowe zastosowanie kompleksu fosfor-azot-metal
TW553243U (en) Structure of clotheshanger
TW582219U (en) Improved structure of flabellum
IL165356A0 (en) Preparation of 4-haloalkylkylnicotinamides
PL356853A1 (en) Application of bacteriphages
TW515461U (en) Improved structure of squat nightstool
SI1537210T1 (sl) Lazna oligonukleotidna inhibicija ekspresije CD40
TW579826U (en) Structure of retainer
TW571665U (en) Improved structure of pensile case
TW587476U (en) Improved structure of spinning-top
TW567775U (en) Structure of hairtie
TW554790U (en) Structure of screwdriver
GB0314360D0 (en) Prevention of uveitis
TW573602U (en) Avstract of the disclosrte
TW539272U (en) Improved structure of extension line
TW533774U (en) Structure improvement of flyswatter
TW587595U (en) Improvement of life-preserver
TW557718U (en) Structure of brush